Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study

RECOMMENDED

Lung Cancer

Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter Analysis

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Okada M, Ohgino K, Horiuchi K, Sayama K, Arai D, Watase M, Kobayashi K, Terashima T, Ishioka K, Miyawaki M, Sakamaki F, Masuzawa K, Terai H, Yasuda H, Soejima K, Fukunaga K

doi: 10.3390/jcm13247815

RECOMMENDED

Lung Cancer

Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Kawachi H, Tamiya M, Oya Y, Saito G, Taniguchi Y, Matsumoto H, Sato Y, Otsuki T, Suzuki H, Fukuda Y, Tanaka S, Tsukita Y, Uchida J, Sakata Y, Nakatani Y, Shibaki R, Arai D, Okada A, Hara S, Takayama K, Nishino K

doi: 10.1016/j.cllc.2024.07.014

Lung Cancer

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)

Clin Lung Cancer

Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM

doi: 10.1016/j.cllc.2025.05.014

Lung Cancer

Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer

Lung Cancer

Vince M, Naqvi SMH, Pellini B, Verbosky M, Melzer D

doi: 10.1016/j.lungcan.2024.107999

RECOMMENDED

Lung Cancer

Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Research Consortium Study BTCRC LUN 16-081

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Wei CX, Althouse SK, Mamdani H, Hanna NH, Durm GA

doi: 10.1016/j.cllc.2024.12.007

RECOMMENDED

Lung Cancer

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A

doi: 10.1016/j.lungcan.2025.108548

RECOMMENDED

Lung Cancer

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

★ 1 Recommended by Dr Martin Frey, Faculty Member

Front Oncol

Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M

doi: 10.3389/fonc.2025.1526931

RECOMMENDED

Lung Cancer

Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Wallace ND, Xie J, Alexander M, Ball D, Hegi-Johnson F, Plumridge N, Siva S, Shaw M, Harden S, John T, Solomon B, Irving L, Duffy M, Officer A, MacManus M

doi: 10.1016/j.cllc.2025.02.010

Further Publications

Successful stent removal after chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer with airway stenosis: A report of three cases

Respir Med Case Rep

Takigawa Y, Sato K, Minami D, Kudo K, Matsumoto S, Fujiwara M, Ichikawa T, Inoue T, Matsuoka S, Watanabe H, Sato A, Shoda H, Ishikawa N, Fujiwara K, Shibayama T

doi: 10.1016/j.rmcr.2025.102217

Related content

Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter Analysis

Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)

Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer

Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Research Consortium Study BTCRC LUN 16-081

Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study

Successful stent removal after chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer with airway stenosis: A report of three cases